| |
Use of chemotherapy
|
|---|
|
Characteristic
|
Total population (N = 1212)
|
Total chemotherapy (N = 1212)
|
NZ European (N = 924)
|
Māori (N = 218)
|
|---|
| |
n (%)
|
n (%)b
|
p
|
n (%)b
|
n (%)b
|
|---|
|
Overall
|
1212 (100)
|
836 (69.0)
| |
635 (68.7)
|
149 (68.3)
|
|
Age (yrs.)
| | |
<0.001
| | |
|
< 40
|
100 (8.3)
|
90 (90.0)
| |
58 (89.2)
|
18 (90.0)
|
|
40-49
|
338 (27.9)
|
276 (81.7)
| |
200 (81.3)
|
56 (81.2)
|
|
50-59
|
434 (35.8)
|
309 (71.2)
| |
245 (72.5)
|
53 (68.8)
|
|
60-69
|
340 (28.1)
|
161 (47.4)
| |
132 (48.0)
|
22 (42.3)
|
|
Deprivation
| | |
0.402
| | |
|
Dep 1-2
|
139 (11.5)
|
100 (71.9)
| |
88 (71.5)
|
8 (80.0)
|
|
Dep 3-4
|
126 (10.4)
|
89 (70.6)
| |
72 (70.6)
|
12 (75.0)
|
|
Dep 5-6
|
313 (25.8)
|
216 (69.0)
| |
174 (67.7)
|
29 (70.7)
|
|
Dep 7-8
|
315 (26.0)
|
213 (67.6)
| |
160 (67.8)
|
39 (61.9)
|
|
Dep 9-10
|
319 (26.3)
|
218 (68.3)
| |
141 (68.4)
|
61 (69.3)
|
|
Surgical hospital type
| |
0.002
| | |
|
Private
|
406 (33.5)
|
303 (74.6)
| |
271 (74.0)
|
21 (80.8)
|
|
Public
|
806 (66.5)
|
533 (66.1)
| |
364 (65.2)
|
128 (66.7)
|
|
Diagnostic type
| | |
0.033
| | |
|
Screen detected
|
407 (33.6)
|
235 (57.7)
| |
195 (57.9)
|
30 (57.7)
|
|
Non-screen detected
|
805 (66.4)
|
601 (74.7)
| |
440 (75.0)
|
119 (71.7)
|
|
Charlson score
| | |
<0.001
| | |
|
0
|
1056 (87.1)
|
754 (71.4)
| |
582 (70.5)
|
124 (71.7)
|
|
1+
|
156 (12.9)
|
82 (52.6)
| |
53 (53.5)
|
25 (55.6)
|
|
Diagnosis year
| | |
0.003
| | |
|
1999-2002
|
269 (22.2)
|
201 (74.7)
| |
160 (73.7)
|
31 (79.5)
|
|
2003-2006
|
374 (30.9)
|
267 (71.4)
| |
216 (72.5)
|
38 (66.7)
|
|
2007-2009
|
292 (24.1)
|
183 (62.7)
| |
128 (60.7)
|
39 (65.0)
|
|
2010-2012
|
277 (22.9)
|
185 (66.8)
| |
131 (66.2)
|
41 (66.1)
|
|
Grade
| | |
<0.001
| | |
|
Grade I
|
168 (13.9)
|
70 (41.7)
| |
62 (43.4)
|
6 (33.3)
|
|
Grade II
|
617 (50.9)
|
409 (66.3)
| |
305 (66.0)
|
83 (66.9)
|
|
Grade III
|
395 (32.6)
|
340 (86.1)
| |
254 (85.8)
|
57 (83.8)
|
|
Missing
|
32 (2.6)
|
17 (53.1)
| |
14 (60.9)
|
3 (37.5)
|
|
ER/PR status
| | |
<0.001
| | |
|
ER &/or PR +
|
926 (76.4)
|
598 (64.6)
| |
457 (64.3)
|
103 (63.6)
|
|
ER & PR -
|
276 (22.8)
|
233 (84.4)
| |
173 (84.4)
|
46 (83.6)
|
|
Missing
|
10 (0.8)
|
5 (50.0)
| |
5 (62.5)
|
0
|
|
T stage
| | |
<0.001
| | |
|
T1
|
368 (30.4)
|
234 (63.6)
| |
196 (62,6)
|
29 (69.0)
|
|
T2
|
692 (57.1)
|
484 (69.9)
| |
364 (71.4)
|
83 (62.4)
|
|
T3
|
83 (6.8)
|
64 (77.1)
| |
40 (74.1)
|
19 (82.6)
|
|
T4
|
62 (5.1)
|
50 (80.6)
| |
31 (77.5)
|
18 (90.0)
|
|
Missing
|
7 (0.6)
|
4 (55.6)
| |
4 (55.6)
|
0
|
|
N stage
| | |
<0.001
| | |
|
0
|
406 (33.5)
|
223 (54.9)
| |
165 (54.6)
|
37 (50.0)
|
|
1
|
537 (44.3)
|
381 (70.9)
| |
291 (70.0)
|
72 (74.2)
|
|
2+
|
269 (22.2)
|
232 (86.2)
| |
179 (86.9)
|
40 (85.1)
|
|
LVI
| | |
<0.001
| | |
|
Negative
|
783 (64.6)
|
484 (61.8)
| |
362 (61.0)
|
88 (62.0)
|
|
Positive
|
429 (35.4)
|
352 (82.1)
| |
273 (82.5)
|
61 (80.3)
|
|
HER-2
| | |
<0.001
| | |
|
Negative
|
658 (54.3)
|
414 (62.9)
| |
314 (63.2)
|
79 (60.8)
|
|
Equivocal
|
48 (4.0)
|
25 (52.1)
| |
17 (48.6)
|
6 (66.7)
|
|
Positive
|
219 (18.1)
|
188 (85.8)
| |
134 (86.5)
|
37 (80.4)
|
|
Missing
|
287 (23.7)
|
209 (72.8)
| |
170 (71.7)
|
27 (81.8)
|
-
aOnly ER and PR negative cancers ≥10mm and ER and/or PR positive cancers ≥20mm in women <70 years are included
-
bProportion of women who had received chemotherapy in each category
